Company news
Sunshine Biopharma Inc. news in 2026
Sunshine Biopharma Inc.'s news releases, calls and decks from 2026, newest first.
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
October 22, 2026
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
October 9, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
October 8, 2026
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
September 24, 2026
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
September 16, 2026
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
August 31, 2026
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
August 26, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
August 19, 2026
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
August 7, 2026
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
August 4, 2026
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
July 28, 2026
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
July 20, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
June 25, 2026
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
June 1, 2026
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
May 29, 2026
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
May 28, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
May 21, 2026
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
May 18, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
May 18, 2026
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
April 5, 2026